Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49

Showing 26-50 of 49 citing articles:

Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women
Priska Kaufmann, Clemens Muehlan, Marion Anliker‐Ort, et al.
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 10, pp. 1278-1287
Open Access | Times Cited: 2
Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study
Naohisa Uchimura, Mitsutaka Taniguchi, Yu Ariyoshi, et al.
Sleep Medicine (2024) Vol. 122, pp. 27-34
Open Access | Times Cited: 2
Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
Bojan Lalovic, Oneeb Majid, Jagadeesh Aluri, et al.
The Journal of Clinical Pharmacology (2020) Vol. 60, Iss. 12, pp. 1642-1654
Open Access | Times Cited: 18
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Uta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 711-721
Closed Access | Times Cited: 17
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist
Martine Géhin, Jolanta Wierdak, Giancarlo Sabattini, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 810-819
Open Access | Times Cited: 16
Daridorexant for the treatment of insomnia disorder: findings and implications
Jéssica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 11, pp. 1749-1761
Closed Access | Times Cited: 12
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects
Clemens Muehlan, Rob Zuiker, Pierre Peeters, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 40, Iss. 2, pp. 157-166
Closed Access | Times Cited: 17
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
Benjamin Berger, Sander Brooks, Rob Zuiker, et al.
CNS Drugs (2020) Vol. 34, Iss. 12, pp. 1253-1266
Closed Access | Times Cited: 15
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Benjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 6, pp. 2132-2138
Open Access | Times Cited: 13
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin
Isabelle Zenklusen, Clemens Muehlan, Ivan Ulč, et al.
Clinical and Experimental Pharmacology and Physiology (2020) Vol. 47, Iss. 11, pp. 1843-1849
Closed Access | Times Cited: 13
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects
Benjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
European Neuropsychopharmacology (2021) Vol. 51, pp. 90-104
Closed Access | Times Cited: 12
Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies
Makoto Uchiyama, Kazuo Mishima, Tomoko Yagi, et al.
Journal of Sleep Research (2024)
Open Access | Times Cited: 1
Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials
Muayad Albadrani, Muhannad saud albadrani, Hammad Ali Fadlalmola, et al.
International Clinical Psychopharmacology (2022) Vol. 38, Iss. 1, pp. 57-65
Closed Access | Times Cited: 6
Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia
Jadwiga Najib, Yuliana Toderika, Lorena Dima
American Journal of Therapeutics (2023) Vol. 30, Iss. 4, pp. e360-e368
Closed Access | Times Cited: 3
From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs
Christine Brotschi, Martin H. Bolli, John Gatfield, et al.
ChemMedChem (2020) Vol. 15, Iss. 5, pp. 430-448
Closed Access | Times Cited: 6
DARIDOREXANT

Prescriber's Guide (2024), pp. 207-210
Closed Access
The Orexin system as a new approach for the improvement of sleep and daytime activity: an innovative therapy option for the treatment of chronic insomnia
Ingo Fietze, Göran Hajak, Heike Beneš, et al.
Somnologie - Schlafforschung und Schlafmedizin (2024)
Open Access
A comprehensive review of Dual Orexin Receptor Antagonist (DORA), Daridorexant: Novel drug for sleep and related disorders
Saurav Misra, Manmeet Kaur, Jayant Kumar Kairi
International journal of life sciences, biotechnology and pharma research. (2024) Vol. 13, Iss. 6, pp. 20-29
Open Access
Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function
Massimo Magliocca, Ingrid Koopmans, Cédric Vaillant, et al.
Journal of Psychopharmacology (2024)
Closed Access
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers
Sander Brooks, Rob Zuiker, Cathy Bleys, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 6, pp. 577-589
Open Access | Times Cited: 1
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects
Marion Anliker‐Ort, Jasper Dingemanse, Luboš Janů, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 11, pp. 827-837
Closed Access | Times Cited: 1
Daridorexant: A drug to treat insomnia
Harsh Tyagi, Amit Sharma, Nikita Khera, et al.
Pharmaspire (2023) Vol. 15, Iss. 02, pp. 80-86
Open Access
Previous Page - Page 2

Scroll to top